Literature DB >> 18307280

Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.

Christina Lönnroth1, Marianne Andersson, Annette Arvidsson, Svante Nordgren, Hans Brevinge, Kristina Lagerstedt, Kent Lundholm.   

Abstract

This study evaluates HLA gene expression and tumor infiltration by B-cells, macrophages, dendritic cells, T-helper and cytotoxic T-lymphocytes in response to short-term preoperative treatment with cyclooxygenase inhibitors. Patients with colorectal carcinoma were randomized to receive oral NSAID (indomethacin or celebrex) for three days preoperatively; controls received esomeprazol. Peroperative tumor biopsies and normal colon tissue were analyzed by microarray, quantitative PCR and immunohistochemistry. Efficacy of short-term systemic NSAID treatment was confirmed by measurement of PGE2 production in blood monocytes from healthy volunteers. NSAID treatment upregulated genes at the MHC locus on chromosome 6p21 in tumor tissue, but not in normal colon tissue, from the same patient. 23 of the 100 most upregulated genes belonged to MHC class II. HLA-DM, -DO (peptide loading), HLA-DP, -DQ, -DR (antigen presentation), granzyme B, H, perforin and FCGR3A (CD16) (cytotoxicity) displayed increased expression, as did CD8, a marker of cytotoxic T-lymphocytes, while HLA-A and -C expression were not increased by NSAID treatment. MHC II protein (HLA-DP, -DQ, -DR) levels and infiltration by CD4+ T-helper cells of tumor stroma increased upon NSAID treatment, while CD8+ cytotoxic T-lymphocytes increased in both tumor stroma and epithelium. Molecules associated with immunosuppressive T regulatory cells (FOXP3, IL-10) were significantly decreased in indomethacin-exposed tumors. Standard oral administration of NSAID three days preoperatively was enough to increase tumor infiltration by seemingly activated immune cells. These findings agree with previous information that high prostanoid activities in colorectal cancer increase the risk for reduced disease-specific survival following tumor resection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18307280      PMCID: PMC2935782     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  71 in total

Review 1.  Helping the CD8(+) T-cell response.

Authors:  Michael J Bevan
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors.

Authors:  Christian Cahlin; Johan Gelin; Marianne Andersson; Christina Lönnroth; Kent Lundholm
Journal:  Int J Oncol       Date:  2005-10       Impact factor: 5.650

4.  The effect of parenteral indomethacin on T-lymphocyte subpopulations and cytokine production in patients under major surgical operations.

Authors:  C A Gogos; J Maroulis; N C Zoumbos; B Salsa; F Kalfarentzos
Journal:  Res Exp Med (Berl)       Date:  1995

5.  A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2.

Authors:  Huie Jing; Jui-Hung Yen; Doina Ganea
Journal:  J Biol Chem       Date:  2004-10-21       Impact factor: 5.157

6.  Immunotherapy of Human Melanoma With Gene-Modified Tumor Cell Vaccines.

Authors: 
Journal:  Cancer Control       Date:  1995-10       Impact factor: 3.302

7.  Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells.

Authors:  Huie Jing; Evros Vassiliou; Doina Ganea
Journal:  J Leukoc Biol       Date:  2003-08-01       Impact factor: 4.962

8.  CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer.

Authors:  Dingzhi Wang; Haibin Wang; Joanne Brown; Takiko Daikoku; Wei Ning; Qiong Shi; Ann Richmond; Robert Strieter; Sudhansu K Dey; Raymond N DuBois
Journal:  J Exp Med       Date:  2006-03-27       Impact factor: 14.307

9.  CD4 T cells and their role in antitumor immune responses.

Authors:  R E Toes; F Ossendorp; R Offringa; C J Melief
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

10.  Influence of pathological tumour variables on long-term survival in resectable gastric cancer.

Authors:  A Cuschieri; I C Talbot; S Weeden
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

View more
  26 in total

1.  Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

Authors:  Gregory T Wolf; Willard E Fee; Robert W Dolan; Jeffrey S Moyer; Michael J Kaplan; Paul M Spring; James Suen; Daniel E Kenady; Jason G Newman; William R Carroll; M Boyd Gillespie; Scott M Freeman; Lorraine Baltzer; Terry D Kirkley; Harvey J Brandwein; John W Hadden
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

Review 2.  Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad.

Authors:  Maciej Chichlowski; Laura P Hale
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-16       Impact factor: 4.052

3.  The tumor microenvironment in colorectal carcinogenesis.

Authors:  Vijay G Peddareddigari; Dingzhi Wang; Raymond N Dubois
Journal:  Cancer Microenviron       Date:  2010-03-05

Review 4.  Perioperative events influence cancer recurrence risk after surgery.

Authors:  Jonathan G Hiller; Nicholas J Perry; George Poulogiannis; Bernhard Riedel; Erica K Sloan
Journal:  Nat Rev Clin Oncol       Date:  2017-12-28       Impact factor: 66.675

Review 5.  T-regulatory cells: key players in tumor immune escape and angiogenesis.

Authors:  Andrea Facciabene; Gregory T Motz; George Coukos
Journal:  Cancer Res       Date:  2012-05-01       Impact factor: 12.701

Review 6.  [Interaction of anesthetics and analgesics with tumor cells].

Authors:  A Bundscherer; M Malsy; D Bitzinger; B M Graf
Journal:  Anaesthesist       Date:  2014-04       Impact factor: 1.041

Review 7.  Immunogenic cell death in colon cancer prevention and therapy.

Authors:  Hang Ruan; Brian J Leibowitz; Lin Zhang; Jian Yu
Journal:  Mol Carcinog       Date:  2020-03-25       Impact factor: 4.784

Review 8.  Enhancing immune responses to tumor-associated antigens.

Authors:  Jack P Higgins; Michael B Bernstein; James W Hodge
Journal:  Cancer Biol Ther       Date:  2009-08-01       Impact factor: 4.742

9.  In vitro effects of meloxicam on the number, Foxp3 expression, production of selected cytokines, and apoptosis of bovine CD25+CD4+ and CD25-CD4+ cells.

Authors:  Tomasz Maślanka; Jerzy Jan Jaroszewski
Journal:  J Vet Sci       Date:  2013-04-30       Impact factor: 1.672

10.  A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.

Authors:  Rita D Brandão; Jürgen Veeck; Koen K Van de Vijver; Patrick Lindsey; Bart de Vries; Catharina H M J van Elssen; Marinus J Blok; Kristien Keymeulen; Torik Ayoubi; Hubert J M Smeets; Vivianne C Tjan-Heijnen; Pierre S Hupperets
Journal:  Breast Cancer Res       Date:  2013-04-08       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.